RAMPS VS SRPS for Pancreatic Body and Tail Adenocarcinoma

Inclusion criteria

• Age 18-80 years old;
• Resectable pancreatic body and tail ductal adenocarcinoma with both preoperative and intraoperative evaluation(refer to NCCN guideline 2018 of Pancreatic Cancer);
• ECOG Performance Status 0-1;
• Adenocarcinoma of pancreatic body and tail duct, without distant metastasis and ascites;
• The estimated survival time is ≥ 3 months;
• Follow-up in time and obey the research requirements;
• Be voluntary to this clinical trial and can sign the informed consent;
• Normal hematological index (Leukocyte, platelet, liver function, renal function, DIC, electrolyte index, Hb >10g/dL).

Exclusion criteria

• The patients with distant metastasis according to preoperative tumor staging;
• Patients with recurrent pancreatic ductal adenocarcinoma;
• The artery or vein is involved and could not be resected or reconstructed(according to preoperative evaluation or intraoperative evaluation after exploration);
• Patients with cardiopulmonary disfunction and cannot tolerate operation;
• The patients accepted neoadjuvant chemotherapy and radiotherapy before operation;
• Patients with other malignancies or hematopathy
• Before the operation, the total bilirubin was more than 250 μmol/L without preoperative biliary drainage or after biliary drainage, the total bilirubin was still more than 250 μmol/L;
• Pregnancy diagnosed, planned pregnancy and lactating female patients
• Refusal to sign consent.
• Intraoperative exclusion include:Tumor metastasis; not pancreatic primary disease; unresectable pancreatic body/tail adenocarcinoma
• Postoperative exclusion include: not pancreatic ductal adenocarcinoma according to pathological examination.
• Withdrawal of informed consent;
• Willingness to withdraw from the study.